

# Ioannis Karakikes

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4477861/ioannis-karakikes-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49 papers	1,782 citations	22 h-index	42 g-index
58 ext. papers	2,279 ext. citations	9.5 avg, IF	4.38 L-index

#	Paper	IF	Citations
49	Generation of a dual edited human induced pluripotent stem cell Myl7-GFP reporter line with inducible CRISPRi/dCas9.. <i>Stem Cell Research</i> , <b>2022</b> , 61, 102754	1.6	
48	SARS-CoV-2 Susceptibility and Gene Variations Within Diverse Ethnic Backgrounds.. <i>Frontiers in Genetics</i> , <b>2022</b> , 13, 888025	4.5	0
47	Translating genomic insights into cardiovascular medicine: Opportunities and challenges of CRISPR-Cas9. <i>Trends in Cardiovascular Medicine</i> , <b>2021</b> , 31, 341-348	6.9	1
46	Generation of AAVS1 integrated doxycycline-inducible CRISPR-Prime Editor human induced pluripotent stem cell line. <i>Stem Cell Research</i> , <b>2021</b> , 57, 102610	1.6	1
45	Small-molecule probe reveals a kinase cascade that links stress signaling to TCF/LEF and Wnt responsiveness. <i>Cell Chemical Biology</i> , <b>2021</b> , 28, 625-635.e5	8.2	3
44	Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy. <i>Circulation</i> , <b>2021</b> , 144, 382-392	16.7	7
43	Pharmacological Silencing of MicroRNA-152 Prevents Pressure Overload-Induced Heart Failure. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006298	7.6	8
42	iPSC Modeling of RBM20-Deficient DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy. <i>Cell Reports</i> , <b>2020</b> , 32, 108117	10.6	13
41	Endogenous Retrovirus-Derived lncRNA BANCRC Promotes Cardiomyocyte Migration in Humans and Non-human Primates. <i>Developmental Cell</i> , <b>2020</b> , 54, 694-709.e9	10.2	16
40	A Novel Recessive Mutation in SPEG Causes Early Onset Dilated Cardiomyopathy. <i>PLoS Genetics</i> , <b>2020</b> , 16, e1009000	6	10
39	Molecular Signatures of Beneficial Class Effects of Statins on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Circulation</i> , <b>2020</b> , 141, 1208-1210	16.7	2
38	A Novel Recessive Mutation in SPEG Causes Early Onset Dilated Cardiomyopathy <b>2020</b> , 16, e1009000		
37	A Novel Recessive Mutation in SPEG Causes Early Onset Dilated Cardiomyopathy <b>2020</b> , 16, e1009000		
36	A Novel Recessive Mutation in SPEG Causes Early Onset Dilated Cardiomyopathy <b>2020</b> , 16, e1009000		
35	A Novel Recessive Mutation in SPEG Causes Early Onset Dilated Cardiomyopathy <b>2020</b> , 16, e1009000		
34	Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology. <i>Stem Cells Translational Medicine</i> , <b>2019</b> , 8, 758-767	6.9	4
33	Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy. <i>Nature</i> , <b>2019</b> , 572, 335-340	50.4	75

32	AlleleProfilerR: A versatile tool to identify and profile sequence variants in edited genomes. <i>PLoS ONE</i> , <b>2019</b> , 14, e0226694	3.7	3
31	A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay. <i>Circulation</i> , <b>2019</b> , 139, 799-811	16.7	54
30	SETD7 Drives Cardiac Lineage Commitment through Stage-Specific Transcriptional Activation. <i>Cell Stem Cell</i> , <b>2018</b> , 22, 428-444.e5	18	20
29	Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling. <i>Stem Cells</i> , <b>2018</b> , 36, 265-277	5.8	74
28	Recent Progress in Genome Editing Approaches for Inherited Cardiovascular Diseases. <i>Current Cardiology Reports</i> , <b>2018</b> , 20, 58	4.2	2
27	Telomere shortening is a hallmark of genetic cardiomyopathies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 9276-9281	11.5	30
26	Concise Review: Mending a Broken Heart: The Evolution of Biological Therapeutics. <i>Stem Cells</i> , <b>2017</b> , 35, 1131-1140	5.8	8
25	A Comprehensive TALEN-Based Knockout Library for Generating Human-Induced Pluripotent Stem Cell-Based Models for Cardiovascular Diseases. <i>Circulation Research</i> , <b>2017</b> , 120, 1561-1571	15.7	37
24	Gene Transfer in Cardiomyocytes Derived from ES and iPS Cells. <i>Methods in Molecular Biology</i> , <b>2017</b> , 1521, 183-193	1.4	2
23	Efficient Genome Editing in Induced Pluripotent Stem Cells with Engineered Nucleases In Vitro. <i>Methods in Molecular Biology</i> , <b>2017</b> , 1521, 55-68	1.4	4
22	Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers. <i>Cell Stem Cell</i> , <b>2017</b> , 20, 490-504.e5	18	117
21	Molecular and functional resemblance of differentiated cells derived from isogenic human iPSCs and SCNT-derived ESCs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E111111-E11120	11.5	47
20	Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. <i>ELife</i> , <b>2017</b> , 6,	8.9	61
19	Current Status of Genome Editing in Cardiovascular Medicine <b>2016</b> , 107-126		1
18	Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. <i>Cell Stem Cell</i> , <b>2016</b> , 19, 311-25	18	103
17	iPSC-derived cardiomyocytes reveal abnormal TGF- $\beta$ signalling in left ventricular non-compaction cardiomyopathy. <i>Nature Cell Biology</i> , <b>2016</b> , 18, 1031-42	23.4	103
16	Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. <i>European Heart Journal</i> , <b>2016</b> , 37, 3282-3284	9.5	42
15	Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. <i>Circulation Research</i> , <b>2015</b> , 117, 80-8	15.7	252

14	A Rapid, High-Quality, Cost-Effective, Comprehensive and Expandable Targeted Next-Generation Sequencing Assay for Inherited Heart Diseases. <i>Circulation Research</i> , <b>2015</b> , 117, 603-11	15.7	27
13	Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction. <i>Journal of the American Society of Hypertension</i> , <b>2015</b> , 9, 975-84.e3		11
12	Phospholamban as a crucial determinant of the inotropic response of human pluripotent stem cell-derived ventricular cardiomyocytes and engineered 3-dimensional tissue constructs. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2015</b> , 8, 193-202	6.4	23
11	Effectiveness of gene delivery systems for pluripotent and differentiated cells. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2015</b> , 2, 14067	6.4	31
10	Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. <i>Nature Communications</i> , <b>2015</b> , 6, 6955	17.4	119
9	Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. <i>Stem Cells Translational Medicine</i> , <b>2014</b> , 3, 18-31	6.9	110
8	Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. <i>Molecular Therapy</i> , <b>2014</b> , 22, 2038-2045	11.7	53
7	Rapid and efficient conversion of integration-free human induced pluripotent stem cells to GMP-grade culture conditions. <i>PLoS ONE</i> , <b>2014</b> , 9, e94231	3.7	36
6	Human-induced pluripotent stem cell models of inherited cardiomyopathies. <i>Current Opinion in Cardiology</i> , <b>2014</b> , 29, 214-9	2.1	22
5	Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000078	6	190
4	Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts. <i>Molecular Therapy</i> , <b>2012</b> , 20, 565-71	11.7	32
3	Expression of cardiac specific genes and functional testing of engineered cardiac tissues. <i>FASEB Journal</i> , <b>2011</b> , 25, 1127.3	0.9	
2	Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a. <i>PLoS ONE</i> , <b>2009</b> , 4, e6474	3.7	26
1	SARS-CoV-2 susceptibility and ACE2 gene variations within diverse ethnic backgrounds		1